-
1
-
-
0035944825
-
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
-
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
-
(2001)
Lancet
, vol.358
, pp. 1754-1759
-
-
van der Lely, A.J.1
Hutson, R.K.2
Trainer, P.J.3
Besser, G.M.4
Barkan, A.L.5
Katznelson, L.6
Klibanski, A.7
Herman-Bonert, V.8
Melmed, S.9
Vance, M.L.10
Freda, P.U.11
Stewart, P.M.12
Friend, K.E.13
Clemmons, D.R.14
Johannsson, G.15
Stavrou, S.16
Cook, D.M.17
Phillips, L.S.18
Strasburger, C.J.19
Hackett, S.20
Zib, K.A.21
Davis, R.J.22
Scarlett, J.A.23
Thorner, M.O.24
more..
-
2
-
-
0033305394
-
Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH
-
Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC & Bennett WF. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. Journal of Clinical Endocrinology and Metabolism 1999 84 2098-2103.
-
(1999)
Journal of Clinical Endocrinology and Metabolism
, vol.84
, pp. 2098-2103
-
-
Thorner, M.O.1
Strasburger, C.J.2
Wu, Z.3
Straume, M.4
Bidlingmaier, M.5
Pezzoli, S.S.6
Zib, K.7
Scarlett, J.C.8
Bennett, W.F.9
-
3
-
-
0003289231
-
A six week, double blind, placebo controlled study of a growth hormone antagonist B2036-PEG (Troverte™), in acromegalic patients
-
New Orleans, LA p Abstract OR4-1
-
Van der Lely AJ, Lamberts SWJ, Barkan A, Pandya N, Besser GM, Trainer PJ, Bonert V, Melmed S, Clemmons DR, Rose R, Vance ML, Thorner MO, Zib KA, Davis RJ, Bennett WF, Scarlett JA. A six week, double blind, placebo controlled study of a growth hormone antagonist B2036-PEG (Troverte™), in acromegalic patients. Program of the 80th annual meeting of the Endocrine Society, New Orleans, LA p57 (Abstract OR4-1) 1998.
-
(1998)
Program of the 80th annual meeting of the Endocrine Society
, pp. 57
-
-
Van der Lely, A.J.1
Lamberts, S.W.J.2
Barkan, A.3
Pandya, N.4
Besser, G.M.5
Trainer, P.J.6
Bonert, V.7
Melmed, S.8
Clemmons, D.R.9
Rose, R.10
Vance, M.L.11
Thorner, M.O.12
Zib, K.A.13
Davis, R.J.14
Bennett, W.F.15
Scarlett, J.A.16
-
4
-
-
85137138074
-
-
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, BennettWF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 20 1171-1177.
-
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, BennettWF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 20 1171-1177.
-
-
-
-
5
-
-
15944375488
-
Alternate day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly
-
Jehle S, Reyes CM, Sundeen RE & Freda PU. Alternate day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1588-1593.
-
(2005)
Journal of Clinical Endocrinology and Metabolism
, vol.90
, pp. 1588-1593
-
-
Jehle, S.1
Reyes, C.M.2
Sundeen, R.E.3
Freda, P.U.4
-
6
-
-
18744389775
-
-
Feenstra J, de Herder WW, ten Have SM, van den Beld AV, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogs and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
-
Feenstra J, de Herder WW, ten Have SM, van den Beld AV, Feelders RA, Janssen JA & van der Lely AJ. Combined therapy with somatostatin analogs and weekly pegvisomant in active acromegaly. Lancet 2005 365 1644-1646.
-
-
-
-
7
-
-
36849041110
-
Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly
-
Neggers S, van Aken MO, Janssen J, Feelders RA, de Herder WW & ven der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601.
-
(2007)
Journal of Clinical Endocrinology and Metabolism
, vol.92
, pp. 4598-4601
-
-
Neggers, S.1
van Aken, M.O.2
Janssen, J.3
Feelders, R.A.4
de Herder, W.W.5
ven der Lely, A.J.6
-
8
-
-
21244495705
-
Quality of life (QOL) in patients with acromegaly is severely impaired: Use of a novel measure of QOL: acromegaly quality of life questionnaire
-
Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM & Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. Journal of Clinical Endocrinology and Metabolism 2005 90 3337-3341.
-
(2005)
Journal of Clinical Endocrinology and Metabolism
, vol.90
, pp. 3337-3341
-
-
Rowles, S.V.1
Prieto, L.2
Badia, X.3
Shalet, S.M.4
Webb, S.M.5
Trainer, P.J.6
-
9
-
-
20244383254
-
Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF1) and IGF-binding protein 3 (IGFBP-3)
-
Elmlinger MW, Kühnel W, Weber MM & Ranke MB. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF1) and IGF-binding protein 3 (IGFBP-3). Clinical Chemistry and Laboratory Medicine 2004 42 654-664.
-
(2004)
Clinical Chemistry and Laboratory Medicine
, vol.42
, pp. 654-664
-
-
Elmlinger, M.W.1
Kühnel, W.2
Weber, M.M.3
Ranke, M.B.4
-
10
-
-
77949270852
-
Endogenous estradiol may influence IGF1 levels in acromegalic women treated with pegvisomant
-
In Press,DOI: 10.1007/s11102-008-0131-5
-
Roemmler J, Bidlingmaier M & Schopol J. Endogenous estradiol may influence IGF1 levels in acromegalic women treated with pegvisomant. Pituitary, 2008. In Press,DOI: 10.1007/s11102-008-0131-5.
-
(2008)
Pituitary
-
-
Roemmler, J.1
Bidlingmaier, M.2
Schopol, J.3
-
11
-
-
0035095755
-
Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance
-
Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ & van der Lely AJ. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. Journal of Clinical Endocrinology and Metabolism 2001 86 590-593.
-
(2001)
Journal of Clinical Endocrinology and Metabolism
, vol.86
, pp. 590-593
-
-
Muller, A.F.1
Janssen, J.A.2
Hofland, L.J.3
Lamberts, S.W.4
Bidlingmaier, M.5
Strasburger, C.J.6
van der Lely, A.J.7
-
12
-
-
33846040409
-
Gender, body weight, disease activity and previous radiotherapy influence the response to pegvisomant
-
Parkinson C, Burman P, Messig M & Trainer PJ. Gender, body weight, disease activity and previous radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2007 92 190-195.
-
(2007)
Journal of Clinical Endocrinology and Metabolism
, vol.92
, pp. 190-195
-
-
Parkinson, C.1
Burman, P.2
Messig, M.3
Trainer, P.J.4
|